The funding will enable the company to expand into the segment of HealthCare Service offerings, both in terms of geography and operations
HK inno.N Corporation will be responsible for the manufacture and supply of Tegoprazan, while Dr. Reddy's will handle local clinical development, registration, marketing and sales
According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
Pioneering Medicines and Novo Nordisk Bio Innovation Hub will leverage Flagship Pioneering’s bioplatform companies to create a portfolio of research programmes within cardiometabolic and rare diseases
The new framework collaboration will support due diligence into ALSA’s potential investments, which will assist with their investment de-risking
Omega plans to further strengthen its capabilities, deepen domain expertise and build new solutions
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market
Pfizer to commercialize NURTEC ODT (rimegepant), an innovative compound for the prevention and acute treatment of migraine, a condition with high unmet need
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
Myovant to receive an upfront payment of US $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to US $90.5 million
Subscribe To Our Newsletter & Stay Updated
